Patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) treated with pralatrexate have previously shown superior overall survival (OS) compared to those who underwent conventional chemotherapy (CC, 15.4 vs. 4.07 months). We conducted an economic evaluation of pralatrexate from a societal perspective in Korea based on data from the PROPEL phase II study. Using a Markov model with a weekly cycle, we simulated the experience of patients with R/R PTCL receiving pralatrexate or CC for 15 years. The model consists of five health states; initial treatment, treatment pause, subsequent treatment, stem cell transplantation (SCT) success, and death. Comparative effectiveness was based on PROPEL phase II single-arm study and its matched historical control analysis. Costs included drug, drug administration, monitoring, adverse event management, and SCT costs. The incremental cost-effectiveness ratio of the base case was $39,153 per quality-adjusted life-year (QALY) gained. The results of one-way sensitivity analysis ranged from $33,949 to $51,846 per QALY gained, which remained within an implicit willingness-to-pay (WTP) threshold of anticancer drugs in Korea. Pralatrexate is a cost-effective intervention with improved OS and incremental costs within the WTP limit. Pralatrexate could function as a new therapeutic option for patients suffering from life-threatening R/R PTCL.

中文翻译：

---

基于病例对照的历史对照研究和单臂临床试验对复发性或难治性外周T细胞淋巴瘤进行普雷西酯的成本-效用分析

与接受常规化学疗法的患者相比，使用普拉拉塞特治疗的复发性或难治性外周T细胞淋巴瘤（R / R PTCL）患者先前显示出更好的总体生存（OS）（CC，15.4 vs. 4.07个月）。我们根据PROPEL II期研究的数据，从社会角度对韩国进行了pralatrexate的经济评估。使用每周周期的马尔可夫模型，我们模拟了R / R PTCL患者接受普拉拉特或CC治疗15年的经验。该模型包括五个健康状态。初始治疗，治疗暂停，后续治疗，干细胞移植（SCT）成功和死亡。比较效果基于PROPEL II期单臂研究及其相匹配的历史对照分析。费用包括药品，药品管理，监测，不良事件管理和SCT费用。基本案例的增量成本效益比为每个质量调整生命年（QALY）$ 39,153。单方面敏感性分析的结果范围为每获得QALY 33,949美元至51,846美元，这仍处于韩国抗癌药物隐含的支付意愿（WTP）阈值之内。Pralatrexate是一种具有成本效益的干预措施，可在WTP限制内改善操作系统并增加成本。对于患有危及生命的R / R PTCL的患者，普拉瑞沙特可以作为一种新的治疗选择。仍处于韩国抗癌药的隐含支付意愿（WTP）阈值之内。Pralatrexate是一种具有成本效益的干预措施，可在WTP限制内改善操作系统并增加成本。对于患有危及生命的R / R PTCL的患者，普拉瑞沙特可以作为一种新的治疗选择。仍处于韩国抗癌药的隐含支付意愿（WTP）阈值之内。Pralatrexate是一种具有成本效益的干预措施，可在WTP限制内改善操作系统并增加成本。对于患有危及生命的R / R PTCL的患者，普拉瑞沙特可以作为一种新的治疗选择。